Persistent low prevalence of hepatitis B vaccination among people with HIV: Time for a change?

Angie Garcia; Karen J. Vigil; Barbara Taylor; Onkar Kshirsagar; Mae Thamer; Mamta K. Jain

doi:10.1111/jvh.13868

Persistent low prevalence of hepatitis B vaccination among people with HIV: Time for a change?

Angie Garcia, Karen J. Vigil, Barbara Taylor, Onkar Kshirsagar, Mae Thamer, Mamta K. Jain

Research output: Contribution to journal › Article › peer-review

Abstract

Hepatitis B virus (HBV) infection is one of the leading causes of hepatocellular carcinoma and mortality among people living with HIV (PLWH). HBV vaccination provides protection from infection; however, vaccination rates are low. We conducted a retrospective analysis at three HIV centres in Texas to determine the proportion of PLWH who received the recommended 3 doses of hepatitis B vaccine within 1 year. Factors associated with vaccination completion were explored. In our sample of three sites in a state with high HIV transmission and high rates of liver disease from 2011 to 2021, showed low rates of hepatitis B vaccination. Among eligible PLWH, only 9% completed the 3-dose hepatitis B vaccine series in 1 year. There is an urgent need to improve HBV vaccination to reach 2030 target for hepatitis B elimination.

Original language	English (US)
Pages (from-to)	790-792
Number of pages	3
Journal	Journal of Viral Hepatitis
Volume	30
Issue number	10
DOIs	https://doi.org/10.1111/jvh.13868
State	Published - Oct 2023

Keywords

HIV
hepatitis B vaccination
practice patterns

ASJC Scopus subject areas

Infectious Diseases
Virology
Hepatology

Access to Document

10.1111/jvh.13868

Cite this

@article{0b4398225e8b4c0e91a514f667be26f6,

title = "Persistent low prevalence of hepatitis B vaccination among people with HIV: Time for a change?",

abstract = "Hepatitis B virus (HBV) infection is one of the leading causes of hepatocellular carcinoma and mortality among people living with HIV (PLWH). HBV vaccination provides protection from infection; however, vaccination rates are low. We conducted a retrospective analysis at three HIV centres in Texas to determine the proportion of PLWH who received the recommended 3 doses of hepatitis B vaccine within 1 year. Factors associated with vaccination completion were explored. In our sample of three sites in a state with high HIV transmission and high rates of liver disease from 2011 to 2021, showed low rates of hepatitis B vaccination. Among eligible PLWH, only 9% completed the 3-dose hepatitis B vaccine series in 1 year. There is an urgent need to improve HBV vaccination to reach 2030 target for hepatitis B elimination.",

keywords = "HIV, hepatitis B vaccination, practice patterns",

author = "Angie Garcia and Vigil, {Karen J.} and Barbara Taylor and Onkar Kshirsagar and Mae Thamer and Jain, {Mamta K.}",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors. Journal of Viral Hepatitis published by John Wiley & Sons Ltd.",

year = "2023",

month = oct,

doi = "10.1111/jvh.13868",

language = "English (US)",

volume = "30",

pages = "790--792",

journal = "Journal of Viral Hepatitis",

issn = "1352-0504",

publisher = "Wiley-Blackwell",

number = "10",

}

TY - JOUR

T1 - Persistent low prevalence of hepatitis B vaccination among people with HIV

T2 - Time for a change?

AU - Garcia, Angie

AU - Vigil, Karen J.

AU - Taylor, Barbara

AU - Kshirsagar, Onkar

AU - Thamer, Mae

AU - Jain, Mamta K.

PY - 2023/10

Y1 - 2023/10

N2 - Hepatitis B virus (HBV) infection is one of the leading causes of hepatocellular carcinoma and mortality among people living with HIV (PLWH). HBV vaccination provides protection from infection; however, vaccination rates are low. We conducted a retrospective analysis at three HIV centres in Texas to determine the proportion of PLWH who received the recommended 3 doses of hepatitis B vaccine within 1 year. Factors associated with vaccination completion were explored. In our sample of three sites in a state with high HIV transmission and high rates of liver disease from 2011 to 2021, showed low rates of hepatitis B vaccination. Among eligible PLWH, only 9% completed the 3-dose hepatitis B vaccine series in 1 year. There is an urgent need to improve HBV vaccination to reach 2030 target for hepatitis B elimination.

AB - Hepatitis B virus (HBV) infection is one of the leading causes of hepatocellular carcinoma and mortality among people living with HIV (PLWH). HBV vaccination provides protection from infection; however, vaccination rates are low. We conducted a retrospective analysis at three HIV centres in Texas to determine the proportion of PLWH who received the recommended 3 doses of hepatitis B vaccine within 1 year. Factors associated with vaccination completion were explored. In our sample of three sites in a state with high HIV transmission and high rates of liver disease from 2011 to 2021, showed low rates of hepatitis B vaccination. Among eligible PLWH, only 9% completed the 3-dose hepatitis B vaccine series in 1 year. There is an urgent need to improve HBV vaccination to reach 2030 target for hepatitis B elimination.

KW - HIV

KW - hepatitis B vaccination

KW - practice patterns

UR - http://www.scopus.com/inward/record.url?scp=85164341905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85164341905&partnerID=8YFLogxK

U2 - 10.1111/jvh.13868

DO - 10.1111/jvh.13868

M3 - Article

C2 - 37401399

AN - SCOPUS:85164341905

SN - 1352-0504

VL - 30

SP - 790

EP - 792

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

IS - 10

ER -

Persistent low prevalence of hepatitis B vaccination among people with HIV: Time for a change?

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this